Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation

Journal of Thoracic and Cardiovascular Surgery

Volumn 148, Issue 3, 2014, Pages 1106-1114

  Mohiuddin, Muhammad M ^a   Singh, Avneesh K ^a   Corcoran, Philip C ^a   Hoyt, Robert F ^b   Thomas III, Marvin L ^c   Ayares, David ^d   Horvath, Keith A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d REVIVICOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANIMALS, NEWBORN; ANTIGENS, CD46; DRUG THERAPY, COMBINATION; GALACTOSYLTRANSFERASES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL CONTRACTION; PAPIO; SWINE; THROMBOMODULIN; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 84908545605     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2014.06.002     Document Type: Conference Paper

References (23)